Latest Lead News

Jayride Group Limited reports a reduced quarterly loss and secures fresh capital, yet faces ongoing uncertainty over its ability to continue as a going concern during its ASX reinstatement process.

Ovanti Limited has raised $3 million through a discounted share placement to fund its expansion into the US buy now, pay later market and support ongoing litigation.

Brightstar Resources has adjusted its November gold production at Laverton Mine down to 4,652 ounces due to processing inefficiencies but remains confident in restoring recovery rates above 90%.

Native Mineral Resources Holdings has locked in a $3 million convertible note raising from Lind Global Fund III LP, with the option to access up to $10 million. The funding aims to bolster working capital and support growth in the Charters Tower region.

Kalamazoo Resources has raised $8 million through a placement and launched a $2 million share purchase plan, aiming to fuel exploration and development across its gold projects.

Panther Metals has completed a $315k shortfall placement, bolstering its funding as it plans deeper drilling at Burtville East and initiates a strategic review of its Coglia project in response to soaring cobalt prices.

Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.

EPX Limited has successfully completed a $2.14 million private placement to institutional investors, positioning itself to acquire Wattwatchers Pty Limited and invest in new technology initiatives. An upcoming Share Purchase Plan will offer existing shareholders further participation opportunities.

Adherium Limited has exceeded its 2025 shipment goals by delivering over 4,600 Hailie® Smartinhaler® devices, including more than 2,000 to Remote Patient Monitoring patients, signaling robust operational momentum.

EVT Limited has acquired the premium QT Auckland hotel for NZ$87.5 million, reinforcing its strategic presence in key city markets while divesting non-core assets to focus on high-performing properties.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

Big River Industries has successfully completed a $10 million entitlement offer, oversubscribed by shareholders, to partly fund its acquisition of Johns Building Supplies in Western Australia.